Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

This single-arm, open-label phase I trial evaluates the safety and tolerability of ICG415, autologous CAR-T cells targeting CD33 and CLL1, in patients with relapsed or refractory acute myeloid leukemia (AML). Subjects receive lymphodepleting chemotherapy followed by autologous CAR-T infusion. The primary goal is to assess safety and preliminary anti-leukemic efficacy in patients failing standard AML therapies.

NCT Number	NCT07668557
Lead Sponsor	iCell Gene Therapeutics
Conditions	Acute Myeloid Leukemia (AML)
Enrollment	18 participants
Start Date	2026-06-10
Primary Completion	2028-07-04 (estimated)
Study Completion	2029-07-04 (estimated)
Updated on ClinicalTrials.gov	2026-06-25